Edina Cenko1, Jinsung Yoon2, Sasko Kedev3, Goran Stankovic4, Zorana Vasiljevic5, Gordana Krljanac4, Oliver Kalpak3, Beatrice Ricci1, Davor Milicic6, Olivia Manfrini1, Mihaela van der Schaar2, Lina Badimon7, Raffaele Bugiardini1. 1. Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy. 2. Department of Electrical and Computer Engineering, University of California, Los Angeles. 3. University Clinic of Cardiology, Medical Faculty, University Ss. Cyril and Methodius, Skopje, Macedonia. 4. Clinical Center of Serbia, Department of Cardiology, Medical Faculty, University of Belgrade, Belgrade, Serbia. 5. Medical Faculty, University of Belgrade, Belgrade, Serbia. 6. Department for Cardiovascular Diseases, University Hospital Center Zagreb, University of Zagreb, Zagreb, Croatia. 7. Cardiovascular Research Institute (ICCC), CiberCV-Institute Carlos III, IIB-Sant Pau, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Barcelona, Spain.
Abstract
Importance: Previous works have shown that women hospitalized with ST-segment elevation myocardial infarction (STEMI) have higher short-term mortality rates than men. However, it is unclear if these differences persist among patients undergoing contemporary primary percutaneous coronary intervention (PCI). Objective: To investigate whether the risk of 30-day mortality after STEMI is higher in women than men and, if so, to assess the role of age, medications, and primary PCI in this excess of risk. Design, Setting, and Participants: From January 2010 to January 2016, a total of 8834 patients were hospitalized and received medical treatment for STEMI in 41 hospitals referring data to the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) registry (NCT01218776). Exposures: Demographics, baseline characteristics, clinical profile, and pharmacological treatment within 24 hours and primary PCI. Main Outcomes and Measures: Adjusted 30-day mortality rates estimated using inverse probability of treatment weighted (IPTW) logistic regression models. Results: There were 2657 women with a mean (SD) age of 66.1 (11.6) years and 6177 men with a mean (SD) age of 59.9 (11.7) years included in the study. Thirty-day mortality was significantly higher for women than for men (11.6% vs 6.0%, P < .001). The gap in sex-specific mortality narrowed if restricting the analysis to men and women undergoing primary PCI (7.1% vs 3.3%, P < .001). After multivariable adjustment for comorbidities and treatment covariates, women under 60 had higher early mortality risk than men of the same age category (OR, 1.88; 95% CI, 1.04-3.26; P = .02). The risk in the subgroups aged 60 to 74 years and over 75 years was not significantly different between sexes (OR, 1.28; 95% CI, 0.88-1.88; P = .19 and OR, 1.17; 95% CI, 0.80-1.73; P = .40; respectively). After IPTW adjustment for baseline clinical covariates, the relationship among sex, age category, and 30-day mortality was similar (OR, 1.56 [95% CI, 1.05-2.3]; OR, 1.49 [95% CI, 1.15-1.92]; and OR, 1.21 [95% CI, 0.93-1.57]; respectively). Conclusions and Relevance: Younger age was associated with higher 30-day mortality rates in women with STEMI even after adjustment for medications, primary PCI, and other coexisting comorbidities. This difference declines after age 60 and is no longer observed in oldest women.
Importance: Previous works have shown that women hospitalized with ST-segment elevation myocardial infarction (STEMI) have higher short-term mortality rates than men. However, it is unclear if these differences persist among patients undergoing contemporary primary percutaneous coronary intervention (PCI). Objective: To investigate whether the risk of 30-day mortality after STEMI is higher in women than men and, if so, to assess the role of age, medications, and primary PCI in this excess of risk. Design, Setting, and Participants: From January 2010 to January 2016, a total of 8834 patients were hospitalized and received medical treatment for STEMI in 41 hospitals referring data to the International Survey of Acute Coronary Syndromes in Transitional Countries (ISACS-TC) registry (NCT01218776). Exposures: Demographics, baseline characteristics, clinical profile, and pharmacological treatment within 24 hours and primary PCI. Main Outcomes and Measures: Adjusted 30-day mortality rates estimated using inverse probability of treatment weighted (IPTW) logistic regression models. Results: There were 2657 women with a mean (SD) age of 66.1 (11.6) years and 6177 men with a mean (SD) age of 59.9 (11.7) years included in the study. Thirty-day mortality was significantly higher for women than for men (11.6% vs 6.0%, P < .001). The gap in sex-specific mortality narrowed if restricting the analysis to men and women undergoing primary PCI (7.1% vs 3.3%, P < .001). After multivariable adjustment for comorbidities and treatment covariates, women under 60 had higher early mortality risk than men of the same age category (OR, 1.88; 95% CI, 1.04-3.26; P = .02). The risk in the subgroups aged 60 to 74 years and over 75 years was not significantly different between sexes (OR, 1.28; 95% CI, 0.88-1.88; P = .19 and OR, 1.17; 95% CI, 0.80-1.73; P = .40; respectively). After IPTW adjustment for baseline clinical covariates, the relationship among sex, age category, and 30-day mortality was similar (OR, 1.56 [95% CI, 1.05-2.3]; OR, 1.49 [95% CI, 1.15-1.92]; and OR, 1.21 [95% CI, 0.93-1.57]; respectively). Conclusions and Relevance: Younger age was associated with higher 30-day mortality rates in women with STEMI even after adjustment for medications, primary PCI, and other coexisting comorbidities. This difference declines after age 60 and is no longer observed in oldest women.
Authors: Jeffrey S Berger; Laine Elliott; Dianne Gallup; Matthew Roe; Christopher B Granger; Paul W Armstrong; R John Simes; Harvey D White; Frans Van de Werf; Eric J Topol; Judith S Hochman; L Kristin Newby; Robert A Harrington; Robert M Califf; Richard C Becker; Pamela S Douglas Journal: JAMA Date: 2009-08-26 Impact factor: 56.272
Authors: Henry H Ting; Elizabeth H Bradley; Yongfei Wang; Judith H Lichtman; Brahmajee K Nallamothu; Mark D Sullivan; Bernard J Gersh; Veronique L Roger; Jeptha P Curtis; Harlan M Krumholz Journal: Arch Intern Med Date: 2008-05-12
Authors: Amit J Shah; Nima Ghasemzadeh; Elisa Zaragoza-Macias; Riyaz Patel; Danny J Eapen; Ian J Neeland; Pratik M Pimple; A Maziar Zafari; Arshed A Quyyumi; Viola Vaccarino Journal: J Am Heart Assoc Date: 2014-06-18 Impact factor: 5.501
Authors: Catherine Gebhard; Monika Maredziak; Michael Messerli; Ronny R Buechel; Fay Lin; Heidi Gransar; Stephan Achenbach; Mouaz H Al-Mallah; Daniele Andreini; Jeroen J Bax; Daniel S Berman; Matthew J Budoff; Filippo Cademartiri; Tracy Q Callister; Hyuk-Jae Chang; Kavitha Chinnaiyan; Benjamin J W Chow; Ricardo C Cury; Augustin DeLago; Gudrun Feuchtner; Martin Hadamitzky; Joerg Hausleiter; Yong-Jin Kim; Jonathon Leipsic; Erica Maffei; Hugo Marques; Pedro de Araújo Gonçalves; Gianluca Pontone; Gilbert L Raff; Ronen Rubinshtein; Leslee J Shaw; Todd C Villines; Yao Lu; Erica C Jones; Jessica M Peña; James K Min; Philipp A Kaufmann Journal: Eur Heart J Cardiovasc Imaging Date: 2020-04-01 Impact factor: 6.875
Authors: Harmony R Reynolds; C Noel Bairey Merz; Colin Berry; Rohit Samuel; Jacqueline Saw; Nathaniel R Smilowitz; Ana Carolina do A H de Souza; Robert Sykes; Viviany R Taqueti; Janet Wei Journal: Circ Res Date: 2022-02-17 Impact factor: 17.367
Authors: M Verdoia; H Suryapranata; S Damen; C Camaro; E Benit; L Barbieri; S Rasoul; H B Liew; J Polad; W A W Ahmad; R Zambahari; J Lalmand; R J van der Schaaf; T H Koh; P Timmermans; D Dilling-Boer; L F Veenstra; A W J Van't Hof; S W L Lee; V Roolvink; E Ligtenberg; S Postma; E J J Kolkman; M A Brouwer; E Kedhi; G De Luca Journal: J Thromb Thrombolysis Date: 2021-04-13 Impact factor: 2.300